Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06326411 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
A Phase 1 study of Melanoma and Glioma, sponsored by Nested Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 230
- Enrollment target
- 20
- Study locations
NCT06326411: Recruiting Phase 1 study of Melanoma and Glioma, sponsored by Nested Therapeutics.
NCT06326411 is a Phase 1 study of Melanoma and Glioma that is actively recruiting participants, run by Nested Therapeutics. The registered enrollment target is 230 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06326411, a Phase 1 study of Melanoma and Glioma, is actively recruiting participants, sponsored by Nested Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 230 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
Primary Outcome
Adverse effects
Conditions Studied
Interventions
- DRUG NST-628
Study Locations (20)
New York
- Roswell Park - Buffalo
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
- Columbia University Medical Center - New York
- Memorial Slone Kettering Cancer Center - New York
Texas
- NEXT Oncology - Austin - Austin
- NEXT Oncology - Dallas - Dallas
- MD Anderson Cancer Center - Houston
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- UCLA Hematology/Oncology - Westwood, Los Angeles
Tennessee
- SCRI Oncology Partners - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
New South Wales
- The Kinghorn Cancer Center, St. Vincent's Health Network - Darlinghurst
- Scientia Clinical Research, Ltd - Randwick
Colorado
- Sarah Cannon Research Institute at Health ONE - Denver
Connecticut
- Yale Cancer Center - New Haven
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2024-04-09 |
| Est. Completion | 2029-11 |
| Phase | Phase 1 |
What NCT06326411 shows while recruiting
NCT06326411 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (67% lower).
The record links to 9 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which NST-628 is the first listed.
NCT06326411 names 20 study sites across 12 states, led by New York, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06326411 about?
NCT06326411 is a clinical study titled "A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors". This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment optio...
What is the current status of trial NCT06326411?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 230 participants. The study started on 2024-04-09. Estimated completion is 2029-11.
What conditions does trial NCT06326411 study?
This clinical trial studies the following conditions: Melanoma, Glioma, Solid Tumor, Adult, NSCLC, Oncology.
What interventions are being tested in trial NCT06326411?
The interventions under investigation include: NST-628 (DRUG).
Who is sponsoring clinical trial NCT06326411?
This trial is sponsored by Nested Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06326411 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06326411's enrollment target sits among peer trials
230 65th of 266 higher than 201 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI